Primary malignant tumours of the bone

Freeman, Alexandra K.; Sumathi, Vaiyapuri P.; Jeys, Lee

doi:10.1016/j.mpsur.2017.10.001

Cited by 5 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be due to more patients presenting as a result of pain, swelling, restriction of limb movement and pathological fractures that occur more commonly in malignant bone tumours. 26 Osteosarcoma was identified as the most common malignant tumour, while chondrosarcoma was the next most common malignant tumour in this study. However, Bahebeck et al revealed osteosarcomas as the most common malignant tumour followed by non-Hodgkin's bone lymphoma, while Ramdass et al in Trinidad and Tobago also had osteosarcoma as the commonest malignant tumour, followed by fibrosarcoma and plasmacytoma.…”

Section: Discussionmentioning

confidence: 64%

Epidemiology of primary bone tumours in Nigeria: a systematic review

2022

View full text Add to dashboard Cite

BACKGROUND: Primary bone tumours, although rare, are an important rising cause of morbidity and mortality in Africa. Late presentation, delayed diagnosis and failure to obtain consent for surgical procedures are important causes of loss of limb and life especially in the West African subregion. Existing data on primary bone tumours in Nigeria have been based on studies performed at various regional levels. The aim of this study is to determine the epidemiological pattern of primary bone tumours in Nigeria in general, including demographics, predominant tumour types and predominant skeletal location by reviewing existing data METHODS: A search of the following databases: University of Edinburgh Library, PubMed, CINAHL and SCOPUS from 2000 till January 2021 following PRISMA guidelines was conducted to identify studies conducted in Nigeria with relevant epidemiological data on primary bone tumours in Nigeria RESULTS: The search yielded a total of 952 hits from which seven hospital-based retrospective studies met the inclusion criteria for review. The estimated incidence rate of primary bone tumours ranged from 0.08 to 0.31 per 100 000 population. All studies showed a male preponderance. The peak age group of individuals presenting with both benign and malignant primary bone tumours was 11-20 years. Overall, benign tumours were more common. Osteochondromas were the most common benign tumours, while the commonest malignant tumours identified were osteosarcomas. The most common location for both benign and malignant tumours were the tibia and fibula CONCLUSION: Nigeria shares some similar epidemiological characteristics of primary bone tumour with other countries; however, some peculiar differences have been identified in this study. Population-based studies are required to obtain more accurate epidemiological data about this disease Level of evidence: Level 2

show abstract

Section: Discussionmentioning

confidence: 64%

Epidemiology of primary bone tumours in Nigeria: a systematic review

2022

View full text Add to dashboard Cite

show abstract

“…The etiology of osteosarcoma is still unclear. However, it is widely accepted that loading stresses and rapid bone growth, which can be attributed to the pubertal growth spurt and regions in the metaphysis of long bones, cause DNA mutations leading to disease [12,44].…”

Section: Primary Bone Cancermentioning

confidence: 99%

“…Ewing sarcoma is a non-complex karyotype sarcoma, as specific gene fusion proteins (e.g., EWS/FLI1) drive tumor oncogenesis [7,42]. It can be characterized by a variety of chromosomal translocations, but 85-90% of cases correspond to the t(11;22)(q24;q12) chromosomal translocation, involving the Ewing sarcoma gene on chromosome 22 and the Friend leukemia virus integration site 1 (FLI1) gene on chromosome 11 [44,49].…”

Section: Primary Bone Cancermentioning

confidence: 99%

See 1 more Smart Citation

Application of additively manufactured 3D scaffolds for bone cancer treatment: a review

2022

View full text Add to dashboard Cite

Bone cancer is a critical health problem on a global scale, and the associated huge clinical and economic burdens are still rising. Although many clinical approaches are currently used for bone cancer treatment, these methods usually affect the normal body functions and thus present significant limitations. Meanwhile, advanced materials and additive manufacturing have opened up promising avenues for the development of new strategies targeting both bone cancer treatment and post-treatment bone regeneration. This paper presents a comprehensive review of bone cancer and its current treatment methods, particularly focusing on a number of advanced strategies such as scaffolds based on advanced functional materials, drug-loaded scaffolds, and scaffolds for photothermal/magnetothermal therapy. Finally, the main research challenges and future perspectives are elaborated.

show abstract

“…Compared to other malignancies, primary bone tumors are quite rare, accounting for only 0.2% of all neoplasms in the UK and USA [2]. This fact certainly limits the data collection of their relative frequency.…”

Section: Introductionmentioning

confidence: 99%

Magnetic Composite Scaffolds for Potential Applications in Radiochemotherapy of Malignant Bone Tumors

et al. 2019

View full text Add to dashboard Cite

Background and objectives: Cancer is the second leading cause of death globally, an alarming but expected increase. In comparison to other types of cancer, malignant bone tumors are unusual and their treatment is a real challenge. This paper’s main purpose is the study of the potential application of composite scaffolds based on biopolymers and calcium phosphates with the inclusion of magnetic nanoparticles in combination therapy for malignant bone tumors. Materials and Methods: The first step was to investigate if X-rays could modify the scaffolds’ properties. In vitro degradation of the scaffolds exposed to X-rays was analyzed, as well as their interaction with phosphate buffer solutions and cells. The second step was to load an anti-tumoral drug (doxorubicin) and to study in vitro drug release and its interaction with cells. The chemical structure of the scaffolds and their morphology were studied. Results: Analyses showed that X-ray irradiation did not influence the scaffolds’ features. Doxorubicin release was gradual and its interaction with cells showed cytotoxic effects on cells after 72 h of direct contact. Conclusions: The obtained scaffolds could be considered in further studies regarding combination therapy for malignant bone tumors.

show abstract

Primary malignant tumours of the bone

Cited by 5 publications

References 4 publications

Epidemiology of primary bone tumours in Nigeria: a systematic review

Epidemiology of primary bone tumours in Nigeria: a systematic review

Application of additively manufactured 3D scaffolds for bone cancer treatment: a review

Magnetic Composite Scaffolds for Potential Applications in Radiochemotherapy of Malignant Bone Tumors

Contact Info

Product

Resources

About